Industry News
Biotechnology Industry News
Cytokinetics may be counting down…
Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficatem. But for a biotech planning to commercialize its first drug—and without Big Pharma backing—the company's CEO Robert
Nxera Pharma has outlined plans to…
Nxera Pharma has outlined plans to lay off 15% of its staff and prioritize its pipeline as part of a push to clear its path to profitability.
Nuvalent has reported phase 1/2…
Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.
A San Diego biotech has set out to…
A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with support from Big Pharma Merck & Co. to fuel its efforts.
The biotech will use the funds to…
The biotech will use the funds to extend its clinical ambitions for its pipeline of DNA-damage-response-inhibiting cancer prospects.
After touting an impressive 1…
After touting an impressive 1 billion-euro-plus fundraising haul back in March, European venture capital firm Sofinnova Partners is back in the spotlight with the close of another flagship fund.
After already halving its…
After already halving its workforce twice since 2022, Sensei Therapeutics is forging ahead with another deep round of cuts.
Merck & Co. is spending $9.2…
Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year.
Bristol Myers Squibb and Johnson…
Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.
Applied Therapeutics’ lack of…
Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question whether the biotech will ever be able to get the drug to market.
Neuro biotech Ovid Therapeutics’…
Neuro biotech Ovid Therapeutics' C-suite is metamorphosing, with co-founder and longtime CEO Jeremy Levin, Ph.D., set to give up the reins. Levin will step down Jan. 1 to make room for Meg Alexander, who will become Ovid’s
European life sciences investor…
European life sciences investor Medicxi has raised 500 million euros (about $581.6 million) to go directly toward innovative biotechs.
Signed, sealed and delivered,…
Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to swoop in and snatch the
Century Therapeutics, Candel…
Century Therapeutics, Candel Therapeutics and MacroGenics have all used their third-quarter earnings releases to disclose how they’re fine-tuning their clinical pipelines to conserve cash.
Third Arc Bio will use Adagene’s…
Third Arc Bio will use Adagene’s precision antibody masking platform—dubbed Safebody—to create new CD3 T-cell engagers against tumor-associated antigens.
Mersana Therapeutics’ decision…
Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid off.
Zealand is pausing development on…
Zealand is pausing development on its dual GLP-1/GLP-2 agonist, known as dapiglutide, as it strives to focus its time and money on “programs with the greatest potential for clinical differentiation and long-term value creation,” the
Korro Bio delivered a double…
Korro Bio delivered a double whammy of bad news, reporting lackluster data on its lead candidate and a pause to its partnership with Novo Nordisk. The biotech, which suffered a 79% stock drop in the
A phase 3 trial of Novartis’…
A phase 3 trial of Novartis’ next-generation malaria treatment has met its primary endpoint, positioning the drugmaker to seek approval of a therapy with the potential to kill drug-resistant parasites.
After forming from a merger hashed…
After forming from a merger hashed out over plates of tacos about a year ago, nChroma Bio is laying off staff and deprioritizing the research spearheaded by one of its founding companies.